Page last updated: 2024-12-11

nicomorphine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nicomorphine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5362460
CHEMBL ID2106851
CHEBI ID135797
SCHEMBL ID26237
MeSH IDM0052495

Synonyms (38)

Synonym
D07285
nicomorphine (inn)
639-48-5
nicomorphine
CHEBI:135797
morphine dinicotinate (ester)
ids-nn-003
CHEMBL2106851
morphinan-3,6alpha-diol, 7,8-didehydro-4,5alpha-epoxy-17-methyl-, dinicotinate (ester)
dea no. 9312
di-o-nicotinoylmorphine
di-nicotinsaeureester von morphin
unii-y95frl95fw
nicomorfina
y95frl95fw ,
nicotinic acid diester with morphine
4,5-eposy-n-methyl-7-morphinen-3,6alpha-diyl bis(nicotinat)
einecs 211-357-9
nicomorphinum [inn-latin]
3,6-dinicotinoylmorphine
nicomorphinum
4,5alpha-epoxy-17-methyl-7-methyl-7-morphinen-3,6-diyldinicotinat
morphine dinicotinate ester
morphine diester with nicotinic acid
nicomorfina [dcit]
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-(5alpha,6alpha)-, di-3-pyridinecarboxylate (ester)
nicomorphine [inn:ban:dcf]
morphine dinicotinate
nicomorphine [inn]
nicomorphine [who-dd]
morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl- (5.alpha.,6.alpha.)-, 3,6-di-3-pyridinecarboxylate
nicomorphine [mi]
morphine ester with nicotinic acid
SCHEMBL26237
DTXSID00213517
DB13454
Q7030497
[(4r,4ar,7s,7ar,12bs)-3-methyl-9-(pyridine-3-carbonyloxy)-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinolin-7-yl] pyridine-3-carboxylate

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The rate of absorption differs between patients and governs the overall pharmacokinetic profile of the compound."( Pharmacokinetics of intramuscular nicomorphine and its metabolites in man.
Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Nijhuis, GM; Vree, TB, 1991
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
"Continuous Reaction Time (CRT) was measured in cancer patients receiving peripherally acting analgesics either alone (n = 16) or in combination with opioids (n = 16)."( Reaction time in cancer patients receiving peripherally acting analgesics alone or in combination with opioids.
Banning, A; Kaiser, F; Sjøgren, P, 1992
)
0.28

Bioavailability

The bioavailability of morphine is directly related to the absorption rate of nicomorphine. Administration of a suppository with 30 mg Nicomorphine gives an excellent absolute bioavailability of 88%.

ExcerptReferenceRelevance
" The rate of absorption differs between patients and governs the overall pharmacokinetic profile of the compound."( Pharmacokinetics of intramuscular nicomorphine and its metabolites in man.
Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Nijhuis, GM; Vree, TB, 1991
)
0.56
" This study shows that administration of a suppository with 30 mg nicomorphine gives an excellent absolute bioavailability of morphine and its metabolites of 88%."( Rectal administration of nicomorphine in patients improves biological availability of morphine and its glucuronide conjugates.
Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Vree, TB, 1994
)
0.83
"29), suggesting it is directly related to the absorption rate of nicomorphine."( The bioavailability of intramuscularly administered nicomorphine (Vilan) with its metabolites and their glucuronide conjugates in surgical patients.
Booij, LH; Dirksen, R; Koopman-Kimenai, PM; Vree, TB, 1995
)
0.78
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
morphinane alkaloidAn isoquinoline alkaloid based on a morphinan skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (54.29)18.7374
1990's13 (37.14)18.2507
2000's2 (5.71)29.6817
2010's0 (0.00)24.3611
2020's1 (2.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.25 (24.57)
Research Supply Index4.03 (2.92)
Research Growth Index4.09 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials18 (48.65%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (51.35%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]